title: Effect of warfarin withdrawal on thrombolytic treatment in patients with ischaemic stroke.
abstract: OBJECTIVE
  Abruptly discontinuing warfarin may induce a rebound prothrombotic state. Thrombolytic agents may also paradoxically induce prothrombotic conditions, which include platelet activation and thrombin generation. Therefore, prothrombotic states may be enhanced by withdrawing warfarin in patients under thrombolytic treatment. This study was aimed to determine whether patients with warfarin withdrawal have different clinical outcomes from those without warfarin use after thrombolytic treatment.
  
  
  METHODS
  A total of 148 consecutive patients with atrial fibrillation who were not on anticoagulants at admission and who received thrombolysis were included in this study. We compared the outcomes between a warfarin withdrawal group and a no-warfarin group.
  
  
  RESULTS
  Fourteen patients (9.5%) were included in the warfarin withdrawal group. Although baseline National Institute of Health Stroke Scale (NIHSS) scores, recanalization rates, and hemorrhage frequencies did not differ between the groups, the warfarin withdrawal group showed poorer outcomes. Increased NIHSS scores during the first 7days were more frequent in the warfarin withdrawal group (57.1% vs. 26.9%, P=0.029). The median percent improvement in NIHSS scores at 24h after thrombolysis was also lower in the warfarin withdrawal group. After adjusting for covariates, warfarin withdrawal was a strong predictor of poor functional outcome at 3months (modified Rankin score≥3) (odds ratio, 17.067, 95% CI 2.703-107.748).
  
  
  CONCLUSIONS
  Discontinuing warfarin was associated with early neurologic deterioration and poor long-term outcomes after thrombolytic treatment.
authors.affiliation: Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Y D
authors.initials: YD
authors.lastname: Kim
authors.forename: J H
authors.initials: JH
authors.lastname: Lee
authors.forename: Y H
authors.initials: YH
authors.lastname: Jung
authors.forename: M-J
authors.initials: MJ
authors.lastname: Cha
authors.forename: H Y
authors.initials: HY
authors.lastname: Choi
authors.forename: C M
authors.initials: CM
authors.lastname: Nam
authors.forename: J H
authors.initials: JH
authors.lastname: Yang
authors.forename: H J
authors.initials: HJ
authors.lastname: Cho
authors.forename: H S
authors.initials: HS
authors.lastname: Nam
authors.forename: K-Y
authors.initials: KY
authors.lastname: Lee
authors.forename: J H
authors.initials: JH
authors.lastname: Heo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020127:Recovery of Function / Q000187:drug effects*; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects; D014568:Urokinase-Type Plasminogen Activator / Q000009:adverse effects; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D014859:Warfarin; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator